Trial · NCT01587196
CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
NCT01587196, Phase 2, Completed, University of Pennsylvania; results first posted 2024-10-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery. Trials, record NCT01587196. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01587196
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
- NCT number
- NCT01587196
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 72 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Prescription Opiate/Medication Dependence
- Interventions
- Vivitrol
- First posted
- 2012-04-30
- Last updated
- 2024-10-15
- Results first posted
- 2024-10-15
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Illicit-positive Urines During Treatment and Follow-up | three months |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Illicit-positive Urines During Treatment and Follow-up | three months | Individuals were tested for presence of opioids: buprenorphine, methadone, opioids, and oxycontin within their urine toxicology | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection One / Buprenorphine | 0 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection One / Methadone | 0 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection One / Opioids | 1 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection One / Oxycontin | 1 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection One / Negative Urine Test | 70 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection Two / Buprenorphine | 2 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection Two / Methadone | 0 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection Two / Opioids | 1 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection Two / Oxycontin | 2 | Participants | |
| Illicit-positive Urines During Treatment and Follow-up | Naltrexone Intervention | Injection Two / Negative Urine Test | 67 | Participants |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Naltrexone Intervention | 72 | |
| Overall Study | COMPLETED | Naltrexone Intervention | 18 | |
| Overall Study | NOT COMPLETED | Naltrexone Intervention | 54 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Naltrexone Intervention | 0 | 72 |
| Total, other adverse events | Naltrexone Intervention | 0 | 72 |
| Total, serious adverse events | Naltrexone Intervention | 0 | 72 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32379516 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01587196
GET https://conductscience.org/api/trials/v1/NCT01587196/registered